Department of Biochemistry and Molecular Biology, College of Basic Medical, Navy Medical University, Shanghai, China.
Department of Pathology, Soochow University Medical School, Suzhou, China.
J Orthop Surg (Hong Kong). 2020 Jan-Apr;28(2):2309499020915989. doi: 10.1177/2309499020915989.
Evidence on the incidence, prevalence, and outcomes of bone metastases among patients with systemic malignancy is limited. This study aimed to evaluate it using the Surveillance, Epidemiology, and End Results (SEER) database.
We collected patients diagnosed with solid malignant tumors deriving outside of the bone, hematologic malignancies, Kaposi sarcoma, lymphoma, and myeloma from the SEER database (from 2010 to 2013). The incidence, prevalence, and outcomes of these systemic malignancies with bone metastases were then analyzed.
A total of 67,605 patients with bone metastases at cancer diagnosis were included. The highest rate of bone metastases was observed in patients with small-cell lung cancer at the time of alternative primary site cancer diagnosis. Among 226,816 cases with metastatic disease, cases with breast cancer (65.58%), and prostate cancer (89.60%) had a high incidence proportion (>10%) of identified bone metastases. Patients with additional bone metastases resulting from prostate cancer, breast cancer, and testis cancer presented the best survival time.
Incidence and prognosis differ considerably among bone metastases with different primary malignancy sites. These results may encourage appropriate application of bone imaging.
关于系统性恶性肿瘤患者骨转移的发生率、患病率和结局的证据有限。本研究旨在使用监测、流行病学和最终结果（SEER）数据库对此进行评估。
我们从 SEER 数据库（2010 年至 2013 年）中收集了诊断为骨外实体恶性肿瘤、血液恶性肿瘤、卡波西肉瘤、淋巴瘤和骨髓瘤的患者。然后分析了这些伴骨转移的系统性恶性肿瘤的发生率、患病率和结局。
共纳入 67605 例癌症诊断时发生骨转移的患者。在其他原发性癌症诊断时，小细胞肺癌患者的骨转移率最高。在 226816 例转移性疾病患者中，乳腺癌（65.58%）和前列腺癌（89.60%）的骨转移发生率比例较高（>10%）。由于前列腺癌、乳腺癌和睾丸癌而发生其他骨转移的患者的生存时间最长。
不同原发恶性肿瘤部位的骨转移发生率和预后有很大差异。这些结果可能鼓励适当应用骨成像。
